DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

Gene Therapy

Volumn 7, Issue 8, 2000, Pages 703-706

  Amici, A ^a   Smorlesi, A ^a   Noce, G ^b   Santoni, G ^a   Cappelletti, P ^a   Capparuccia, L ^a   Coppari, R ^a   Lucciarini, R ^a   Petrelli, C ^a   Provinciali, M ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b INRCA   (Italy)

Author keywords

DNA vaccination; HER 2 neu; Interleukin 12; Mammary tumor; Transgenic mice

Indexed keywords

DNA VACCINE; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER GENETICS; CYTOMEGALOVIRUS; GENE OVEREXPRESSION; IMMUNIZATION; MOUSE; NONHUMAN; ONCOGENE NEU; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; TRANSGENIC MOUSE;

ANIMALIA; CYTOMEGALOVIRUS; MURINAE; MUS MUSCULUS;

EID: 12944254575     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301151     Document Type: Article

References (24)

1. Bargmann CI, Hung UC, Weinberg RA. The neu oncogenes encodes epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230.
2. Coussens L et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
3. Bargmann CI, Hung UC, Weinberg RA. Multiple independent activation of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-657.
4. Bargmann CI, Weinberg RA. Oncogene activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988; 7: 2043-2052.
5. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB related gene in human mammary carcinoma. Science 1985; 229: 974-976.
6. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of Her-2/neu oncogene. Science 1987; 235: 177-182.
7. van de Vijver M et al. Amplification of the neu (c-erbB2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-2023.
8. Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
9. Kern JA et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-5191.
10. Yonemura Y et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 151: 1034-1038.
11. Slamon DJ et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
12. Allred D et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression to in situ invasive breast cancer. Hum Pathol 1992; 23: 974-978.
13. Disis ML et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20.
14. Disis ML et al. Peptide-based but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 1996; 156: 3151-3158.
15. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998; 47: 183-190.
16. Chen Y et al. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res 1998; 58: 1965-1971.
17. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18: 267-268.
18. Coulie PG. Human tumor antigens recognised by T cells: new perspectives for anticancer vaccines? Mol Med Today 1997; 3: 261-268.
19. Gerrard TL, Terz JJ, Kaplan AM. Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int J Cancer 1980; 26: 585-593.
20. Ziegler-Heithbrock HW et al. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res 1986; 46: 5947-5952.
21. Gerrard TL, Cohen DJ, Kaplan AM. Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 1981; 66: 483-488.
22. Colombo MP et al. Amount of interleukin-12 available at the tumor site is critical for tumor progression. Cancer Res 1996; 56: 2531-2534.
23. Kim JJ et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
24. Concetti A et al. Autoantibody to p185 oncoprotein by vaccination with xenogenic DNA. Cancer Immunol Immunother 1996; 43: 307-315.